Literature DB >> 9182886

A cross-reactive idiotype in scleroderma.

D Vázquez-Abad1, L Tian, M Zanetti, N F Rothfield.   

Abstract

Autoantibodies to centromere proteins (anti-CENPs) and to topoisomerase-I are highly specific for scleroderma. Unlike most autoantibodies in other diseases, these autoantibodies are mutually exclusive. We have analysed the idiotypes (Ids) expressed by anti-CENP-B, antitopoisomerase-I, and IgGs from 20 scleroderma patients. Rabbit anti-Ids were prepared to antitopoisomerase-I from two scleroderma patients, and to anti-CENP-B from four patients. These six anti-Ids were used to study the purified autoantibodies from 20 scleroderma patients: four antitopoisomerase-I, 10 anti-CENP-B, and six purified IgG from scleroderma patients who were negative for both autoantibodies. In addition, we studied sera from 40 normal autoantibody-negative controls, and sera and purified immunoglobulins from 17 systemic lupus erythematosus (SLE) patients containing high titres of anti-double-stranded DNA, and/or autoantibodies to extractable nuclear antigens (ENA). Using direct binding, and competitive inhibition ELISAs and immunoblots, we identified an Id present in the heavy chains of all the affinity-purified antitopoisomerase-I, and anti-CENP-B. Interestingly, this Id was also present in the immunoglobulins of the scleroderma patients who had neither of the two autoantibodies. By contrast, cross-reactive Id-EM was not found in the sera or immunoglobulins from 17 SLE patients, or in the sera from 40 normal subjects. Several samples from two patients showed that this cross-reactive Id-EM was stable over time. The scleroderma disease-specific autoantibodies may be identified through a common structural feature at the variable region of the heavy chain: cross-reactive Id-EM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182886      PMCID: PMC1904694          DOI: 10.1046/j.1365-2249.1997.3911292.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  2 in total

1.  Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma.

Authors:  A C Gelber; S R Pillemer; B J Baum; F M Wigley; L K Hummers; S Morris; A Rosen; L Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

2.  Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis.

Authors:  Anne E Tebo; Robert L Schmidt; Tracy M Frech
Journal:  J Rheumatol       Date:  2019-03-01       Impact factor: 4.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.